InsiderTrades.com logo
Jay T. Backstrom net worth and biography
  • Phone
  • Email
  • Website

Jay Backstrom Biography and Net Worth

President & CEO of Scholar Rock

Dr. Jay Backstrom joined Scholar Rock in October 2022 as President & CEO. He is an industry veteran with over 30 years of experience in clinical research and development. Prior to Scholar Rock, he served as Executive Vice President, Research and Development at Acceleron Pharma, from December 2019 through its acquisition by Merck in 2021. Previously, he served as the Chief Medical Officer and Head of Global Regulatory Affairs for Celgene Corporation and spent more than a decade at the company during a time of significant pipeline expansion and revenue growth. Prior to Celgene, Jay served as the Vice President, Global Medical Affairs and Safety at Pharmion and held industry roles at Quintiles, Hoechst Marion Roussel and Marion Merrell Dow. Prior to joining industry, he served as staff physician and medical director of the Samuel U. Rodgers Community Health Center in Kansas City, Missouri. Jay holds an M.D. from Temple University School of Medicine, received post-graduate training in Internal Medicine at Temple University Hospital, and holds an MPH from St. Louis University School of Public Health.

What is Jay T. Backstrom's net worth?

The estimated net worth of Jay T. Backstrom is at least $10.41 million as of February 18th, 2025. Dr. Backstrom owns 311,991 shares of Scholar Rock stock worth more than $10,408,020 as of March 28th. This net worth approximation does not reflect any other assets that Dr. Backstrom may own. Additionally, Dr. Backstrom receives an annual salary of $1,070,000.00 as President & CEO at Scholar Rock. Learn More about Jay T. Backstrom's net worth.

How old is Jay T. Backstrom?

Dr. Backstrom is currently 69 years old. There are 6 older executives and no younger executives at Scholar Rock. Learn More on Jay T. Backstrom's age.

What is Jay T. Backstrom's salary?

As the President & CEO of Scholar Rock Holding Co., Dr. Backstrom earns $1,070,000.00 per year. Learn More on Jay T. Backstrom's salary.

How do I contact Jay T. Backstrom?

The corporate mailing address for Dr. Backstrom and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at chu@scholarrock.com. Learn More on Jay T. Backstrom's contact information.

Has Jay T. Backstrom been buying or selling shares of Scholar Rock?

Over the course of the past ninety days, Jay T. Backstrom has sold $1,662,654.36 in Scholar Rock stock. Most recently, Jay T. Backstrom sold 18,372 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a transaction totalling $676,640.76. Following the completion of the sale, the chief executive officer now directly owns 311,991 shares of the company's stock, valued at $11,490,628.53. Learn More on Jay T. Backstrom's trading history.

Who are Scholar Rock's active insiders?

Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Jeffrey Flier (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), and Tracey Sacco (Chief Commercial Officer). Learn More on Scholar Rock's active insiders.

Are insiders buying or selling shares of Scholar Rock?

In the last year, insiders at the sold shares 20 times. They sold a total of 2,141,013 shares worth more than $67,818,845.02. The most recent insider tranaction occured on March, 24th when insider Tracey Sacco sold 6,500 shares worth more than $215,020.00. Insiders at Scholar Rock own 19.2% of the company. Learn More about insider trades at Scholar Rock.

Information on this page was last updated on 3/24/2025.

Jay T. Backstrom Insider Trading History at Scholar Rock

See Full Table

Jay T. Backstrom Buying and Selling Activity at Scholar Rock

This chart shows Jay T Backstrom's buying and selling at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.66MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Scholar Rock Company Overview

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $33.36
Low: $31.86
High: $33.51

50 Day Range

MA: $37.94
Low: $32.16
High: $46.73

2 Week Range

Now: $33.36
Low: $6.76
High: $46.98

Volume

1,031,085 shs

Average Volume

1,147,327 shs

Market Capitalization

$3.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59